Johannes M. Waldschmidt

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Journal: Nature medicine
Published: July 06, 2026

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Proteome profiling reveals NQO2 activity contributing to proteasome inhibitor resistance in multiple myeloma cell lines.

Journal: Molecular & cellular proteomics : MCP
Published: May 13, 2026

Ultra-High-Resolution Dual-Source Photon-Counting CT for Expanded Characterization of Pathophysiological Imaging Patterns in Multiple Myeloma.

Ultra-High-Resolution Dual-Source Photon-Counting CT for Expanded Characterization of Pathophysiological Imaging Patterns in Multiple Myeloma.

Journal: Investigative radiology
Published: May 05, 2026

Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.

Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: February 20, 2026

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Journal: Leukemia
Published: January 31, 2026

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Journal: Leukemia
Published: December 06, 2025

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Journal: Blood advances
Published: December 01, 2025

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis.

Journal: Blood advances
Published: December 01, 2025

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal
Published: November 01, 2025

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Journal: Nature medicine
Published: September 26, 2025

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.

Journal: Haematologica
Published: September 11, 2025

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Journal: Leukemia
Published: August 15, 2025
Showing 1-12 of 69

Last Updated: 09/26/2026